Sale of Pegzilarginase to Immedica (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Jul. 27, 2023	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Disposal Group, Including Discontinued Operations [Line Items]
Proceeds from sale of in-process research and development asset				$ 70,000	$ 7,000
Gain on sale of in-process research and development asset		$ 40,000	$ 10,000	70,000	$ 10,000
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Global Rights to Pegzilarginase
Disposal Group, Including Discontinued Operations [Line Items]
Proceeds from sale of in-process research and development asset	$ 15,000
Contingent consideration	$ 100,000
Receivable outstanding		$ 3,000		$ 3,000		$ 3,000